

Byoung Dae Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6821120/publications.pdf>

Version: 2024-02-01

25
papers

1,920
citations

430874

18
h-index

580821

25
g-index

25
all docs

25
docs citations

25
times ranked

2829
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. <i>Nature Medicine</i> , 2010, 16, 998-1000.	30.7	342
2	Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson's Disease. <i>Cell</i> , 2014, 157, 472-485.	28.9	239
3	Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11696-11701.	7.1	207
4	Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. <i>Nature Neuroscience</i> , 2013, 16, 1392-1400.	14.8	182
5	GSK3 controls axon growth via CLASP-mediated regulation of growth cone microtubules. <i>Genes and Development</i> , 2011, 25, 1968-1981.	5.9	134
6	Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson's Disease-Related Toxicity in Human Neurons. <i>ACS Chemical Biology</i> , 2011, 6, 1021-1028.	3.4	131
7	Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in <i>Caenorhabditis elegans</i> and <i>Drosophila</i> Parkinson's disease models. <i>Human Molecular Genetics</i> , 2011, 20, 3933-3942.	2.9	120
8	Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. <i>Molecular Neurodegeneration</i> , 2018, 13, 8.	10.8	87
9	Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 1635-1640.	7.1	70
10	Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 365-373.	8.7	69
11	Pathological Functions of LRRK2 in Parkinson's Disease. <i>Cells</i> , 2020, 9, 2565.	4.1	44
12	Poly (ADP-ribose) in the pathogenesis of Parkinson's disease. <i>BMB Reports</i> , 2014, 47, 424-432.	2.4	40
13	Brain injury induces HIF-1 α -dependent transcriptional activation of LRRK2 that exacerbates brain damage. <i>Cell Death and Disease</i> , 2018, 9, 1125.	6.3	39
14	Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond. <i>BMB Reports</i> , 2015, 48, 243-248.	2.4	36
15	Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α -Synuclein Pathology. <i>ENeuro</i> , 2017, 4, ENEURO.0004-17.2017.	1.9	31
16	PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	30
17	High-Performance Conducting Polymer Nanotube-based Liquid-Ion Gated Field-Effect Transistor Aptasensor for Dopamine Exocytosis. <i>Scientific Reports</i> , 2020, 10, 3772.	3.3	29
18	LRRK2 and membrane trafficking: nexus of Parkinson's disease. <i>BMB Reports</i> , 2019, 52, 533-539.	2.4	23

#	ARTICLE	IF	CITATIONS
19	Inflammatory signals induce the expression of tonicity-responsive enhancer binding protein (TonEBP) in microglia. <i>Journal of Neuroimmunology</i> , 2016, 295-296, 21-29.	2.3	19
20	LRRK2 at the Crossroad of Aging and Parkinson's Disease. <i>Genes</i> , 2021, 12, 505.	2.4	17
21	Microtubule-Targeting Agents Enter the Central Nervous System (CNS): Double-edged Swords for Treating CNS Injury and Disease. <i>International Neurology Journal</i> , 2014, 18, 171.	1.2	13
22	Decoding the temporal nature of brain GR activity in the NF- κ B signal transition leading to depressive-like behavior. <i>Molecular Psychiatry</i> , 2021, 26, 5087-5096.	7.9	10
23	Characterization of Parkinson's disease-related pathogenic TMEM230 mutants. <i>Animal Cells and Systems</i> , 2018, 22, 140-147.	2.2	4
24	Improved dynamic monitoring of transcriptional activity during longitudinal analysis in the mouse brain. <i>Biology Open</i> , 2019, 8, .	1.2	2
25	Measuring the Activity of Leucine-Rich Repeat Kinase 2: A Kinase Involved in Parkinson's Disease. <i>Methods in Molecular Biology</i> , 2012, 795, 45-54.	0.9	2